MEDGF (Medacta Group) 6-Month Share Buyback Ratio: 0.17% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEDGF Medacta Group SA MEDGF
71 GF Score
Price $160.00
GF Value $91.08
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medacta Group 6-Month Share Buyback Ratio?

Medacta Group MEDGF +90.68% 71 6-Month Share Buyback Ratio is 0.17 as of Dec. 2025. GuruFocus rates MEDGF with a GF Score™ of 71/100 and a GF Value™ of $91.08 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Medacta Group's current 6-Month Share Buyback Ratio was 0.17%.


Medacta Group  (OTCPK:MEDGF) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Medacta Group 6-Month Share Buyback Ratio Related Terms


MEDGF vs ABT, SYK, MDT: 6-Month Share Buyback Ratio Comparison

For the Medical Devices subindustry, Medacta Group's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medacta Group 6-Month Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Medacta Group's 6-Month Share Buyback Ratio falls into.


MEDGF
71GF Score
Medacta Group SA MEDGF
6-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group 6-Month Share Buyback Ratio Calculation

Medacta Group's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2025 ) - Shares Outstanding (EOP) (Dec. 2025 )) / Shares Outstanding (EOP) (Jun. 2025 )
=(19.945 - 19.911) / 19.945
=0.17%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 6-Month Share Buyback Ratio of 0.17 mean?
Medacta Group (MEDGF) has a 6-Month Share Buyback Ratio of 0.17 as of Dec. 2025. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Medacta Group and its competitors.
Is Medacta Group's 6-Month Share Buyback Ratio too high?
Medacta Group's current 6-Month Share Buyback Ratio is 0.17. Overall, Medacta Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's 6-Month Share Buyback Ratio compare to ABT and SYK?
Medacta Group's 6-Month Share Buyback Ratio of 0.17 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 6-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Medacta Group and its competitors. Medacta Group's current 6-Month Share Buyback Ratio is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $91.08, compared to a current price of $160.00 — trading 75.7% above its estimated fair value. The current 6-Month Share Buyback Ratio is 0.17. Medacta Group's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For Medacta Group (MEDGF), the current 6-Month Share Buyback Ratio is 0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (MEDGF) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be overvalued. The current stock price of $160.00 is trading 75.7% above its estimated GF Value™ of $91.08. GuruFocus considers Medacta Group to be Significantly Overvalued.

Key valuation signals for MEDGF:

  • 6-Month Share Buyback Ratio: 0.17
  • GF Value™: $91.08 vs. price of $160.00 (75.7% above fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
71GF Score

Get the complete analysis for MEDGF

6-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$160.00
Price
$91.08
GF Value